FDA: FDA Safety Communication: Updated information on the risks of thrombosis and hemolysis potentially related to administration of intravenous, subcutaneous and intramuscular human immune globulin products

This update is in follow-up to the FDA Interim Statement Regarding Immune Globulin Intravenous (IGIV), dated August 22, 2002, regarding thrombotic events following IGIV infusion. This Safety Communication provides an update to that information, and addresses hemolysis, another risk potentially associated with the administration of human immune globulin.